Picture 1 of 1

Stock photo

Schmitz - HMG-CoA Reductase Inhibitors - New hardback or cased book - - S555z - Picture 1 of 1

HMG-CoA Reductase Inhibitors by Michael Torzewski, Gerd Schmitz (Hardcover, 2002)

iHaveit (88517)

99.3% positive Feedback

Price:

£173.88

Free postage

Estimated delivery Thu, 19 Jun - Tue, 24 Jun

Returns:

30 days return. Buyer pays for return postage. If you use an eBay delivery label, it will be deducted from your refund amount.

Condition:

New

The Title is HMG-CoA Reductase Inhibitors. The item is a book hardback or cased book. Pages Count - 164. Binding type - Hardcover. Content Language - English. Books are released in many editions and variations, such as standard edition, re-issue, not for sale, promotional, special edition, limited edition, and many other editions and versions.

About this product

Product Information

HMG-CoA reductase inhibitors (statins) are established drugs for the treatment of hypercholesterolemia. Furthermore, they induce regression of vascular atherosclerosis as well as reduction of cardiovascular-related morbidity and death in patients with and without coronary artery disease. This book deals with statins which have substantially altered the approach to therapy of atherosclerosis and its sequelae. Emphasis is placed on the scientific background to the discoveries and the development of the therapy, including an overview of the current state of knowledge of the drugs. Clinical data are reviewed extensively. This book not only provides the reader with valuable information but also stimulates further research into the pathogenesis of atherosclerosis and the mechanisms behind the action of effective statins. It sets the stage for creative thinking among scientists of many disciplines for the accomplishment of our ultimate goals in treating atherosclerosis and its sequelae. This topical volume, written by the leaders in the field, will appeal to medical reseachers, members of the pharmaceutical industry, physicians and all those interested in this latest frontier of treatment of hypercholesterolemia.